US Federal court finds three drug majors guilty of marking up AWPs; levies damages
A US District Judge in the Court of Massachusetts, Boston, has ruled that several drugmakers falsely inflated the prices of their drugs in 2003.
According to the ruling, the defendants, Anglo-Swedish drug major AstraZeneca, Schering-Plough subsidiary Warrick Pharmaceuticals and Bristol-Myers Squibb engaged in unfair and deceptive trade practices that are in violation of Massachusetts laws.
The suit, which was filed by Seattle-based Hagens Berman Sobol Shapiro, targeted the companies' practice of inflating the average wholesale prices (AWP) that the companies reported through publications for certain drugs, including costly chemotherapy agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze